Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis.
about
Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptorImmune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistanceImmune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors.Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients.Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants.A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma.Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis.Is autoimmunity the Achilles' heel of cancer immunotherapy?Melanocytic nevi and melanoma: unraveling a complex relationship.Optimizing T-cell receptor gene therapy for hematologic malignancies.Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.The safety of anti PD-1 therapeutics for the treatment of melanoma.Pembrolizumab Therapy Triggering an Exacerbation of Preexisting Autoimmune Disease: A Report of 2 Patient CasesIntralesional treatment of metastatic melanoma: a review of therapeutic options.Skin Reactions to Immune Checkpoint Inhibitors.Immune and molecular correlates in melanoma treated with immune checkpoint blockade.Two cases of melanomas paradoxically metastasizing to the intestinal tract during nivolumab therapy.Resident memory T cells in the skin mediate durable immunity to melanoma.Targeting cryptic epitope with modified antigen coupled to the surface of liposomes induces strong antitumor CD8 T-cell immune responses in vivo.Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer.Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers.Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy.Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy.Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: A novel findingSequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities.Immunotherapy "Shock" with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma.Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience.Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer.Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry.A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma.Electrochemotherapy and calcium electroporation inducing a systemic immune response with local and distant remission of tumors in a patient with malignant melanoma - a case report.The avidity of tumor-specific T cells amplified by a plasmacytoid dendritic cell-based assay can predict the clinical evolution of melanoma patients.Targeting CTLA-4, PD-L1 and IDO to modulate immune responses in vitiligo.Vitiligo-like lesions and immune checkpoint inhibition therapy: is it truly an adverse event exclusive to patients with melanoma?[Initially undetected de novo psoriasis triggered by nivolumab for metastatic base of the tongue carcinoma].Emerging biomarkers for cancer immunotherapy in melanoma.Impact of a CD4 gene haplotype on the immune response in minipigs.
P2860
Q27323878-AAFD4A6F-A601-4446-AEDE-A3B519BEDDD1Q35979344-370CF9D6-1B83-43DA-8780-5F5ED252F631Q36125878-57270523-7096-44EC-B676-56AB3C544298Q36413957-9A08F8F4-88A8-48EC-943F-F20B04C9C74CQ36586109-BFB3BFBE-DE97-4F38-89C9-B9301711E132Q36992766-3FF61D98-415C-40D9-BFDD-5E3C3B78A5BCQ37432581-DFAAA0FC-C48F-4E51-A8AB-70675F73C2B4Q37518314-92AFFE37-DD57-4054-AF36-D7B2735EE53FQ38566770-5EB32594-4AA5-485D-9CA2-A4C31C829946Q38687375-77209DD4-39EA-4122-9599-20ED75921377Q38730348-66D94120-B0C6-46A7-A5D9-119B8B028F56Q38840466-629145EB-597E-4483-B8D1-7AB33A849C58Q38884560-1F161662-4B0D-44C0-A99A-A63D67DB9EFCQ38916814-371ECE73-08C6-42DE-9461-36C38D487AB8Q38979801-57D2B626-A197-4E6B-9F6A-C60851825A9BQ39003398-C0DA9E0A-E07A-4211-B7AA-891DEF44E44CQ39081034-252B2CA6-F660-4005-9C83-CEC638488460Q39189257-AE53A1B7-2826-42A7-9D0B-631BC87CA2C8Q39329603-48888F12-D5A0-4F5B-AFD4-528DB014313FQ40065192-909AE955-86EC-4D33-A7B4-4B32588CBA37Q40122403-3E5662D8-6B6C-499F-B8E9-3CCD92FA60FCQ40510640-EFD46AB7-DA93-42CB-AE6E-F55819A116D6Q41722598-C5873433-67FE-46DB-A6F2-14AC6DA2FB7DQ41899044-F452B27C-E296-432A-B916-37857150398EQ41930838-7F05814E-E5E3-4FDF-BBCB-BA9DE453B3B3Q42050062-BC391ED3-C23D-44F3-A01D-F166F1D81A9FQ42065866-85322404-90C3-4BA8-8A4A-6975D524C210Q42364915-F0246C42-38D0-4B34-8D89-A9A76B9606A4Q47105617-A2EDAF30-E42A-49FF-91C3-B50AEAFC1CD2Q47211203-BE4B6F0A-9065-4C98-8C58-3DD298D57C5AQ47236362-3FF5F6A5-4CEC-495D-BB50-CA5EE64A40CFQ47287952-6A53021E-14E6-42F6-85EF-7B5DE9499C18Q48301194-5655325B-BF2C-4DA1-87DE-401B3E310D4FQ48350250-452E385B-8583-4692-A2E5-DF99F4E9CC43Q48351257-88914AFB-DB38-4240-BFF0-E24F606FB295Q49048342-FD853B98-C011-4F44-B05F-25C1B9F04558Q50048543-E8C73BC3-77F1-4DC3-8B87-40275273C4F5Q50058093-A4143996-095D-446F-AFFC-A1C85BDF97F4Q50058145-DEC9B3AB-7EE5-45A7-9917-35FC0C1B8A9AQ50101147-A9F16AF5-5AA1-4205-83BC-E4AFE6FEEF50
P2860
Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Vitiligo-like depigmentation i ...... atic review and meta-analysis.
@en
type
label
Vitiligo-like depigmentation i ...... atic review and meta-analysis.
@en
prefLabel
Vitiligo-like depigmentation i ...... atic review and meta-analysis.
@en
P2093
P50
P356
P1476
Vitiligo-like depigmentation i ...... atic review and meta-analysis.
@en
P2093
Aeilko H Zwinderman
Hansje-Eva Teulings
Phyllis I Spuls
Sophia N Jansen
P304
P356
10.1200/JCO.2014.57.4756
P407
P577
2015-01-20T00:00:00Z